Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2

Summary

The goal of this clinical trial is to learn about the efficacy and safety of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic salivary cancer.

Timeline

Start

2022-03-31

Primary completion

2023-03-31

Completion

2023-12-31

Drugs

Indications